ストックスクリーナーアプリを入手
71.28
0.68%
-0.49
前日終値:
$71.77
開ける：
$72.2
24時間の取引高:
454.77K
Relative Volume:
0.80
時価総額：
$3.95B
収益：
$76.81M
当期純損益:
$-162.42M
株価収益率:
-23.84
EPS:
-2.99
ネットキャッシュフロー:
$-122.49M
1週間 パフォーマンス:
-3.78%
1か月 パフォーマンス:
+4.44%
6か月 パフォーマンス:
+11.81%
1年 パフォーマンス:
+7.25%
1日の値動き範囲:
$70.94
$73.33
1週間の範囲:
$69.00
$74.73
52週間の値動き範囲:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
ACLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
71.28 | 3.98B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-03-07 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-04 | 繰り返されました | Needham | Buy |
| 2023-12-19 | 開始されました | Scotiabank | Sector Outperform |
| 2023-10-30 | 開始されました | TD Cowen | Outperform |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-05-18 | 開始されました | Truist | Buy |
| 2023-04-14 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-14 | 開始されました | Stifel | Buy |
| 2023-02-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-13 | 再開されました | BofA Securities | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-27 | 開始されました | Needham | Buy |
| 2022-07-20 | 開始されました | Canaccord Genuity | Buy |
| 2022-03-01 | 開始されました | BofA Securities | Buy |
| 2022-03-01 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Arcellx Inc (ACLX) 最新ニュース
Traders Watching For Reversal Pattern in Arcellx Inc.2025 Price Action Summary & Advanced Technical Signal Analysis - 선데이타임즈
Watch for Bullish Crossover in Arcellx Inc.Options Play & AI Enhanced Market Trend Forecasts - beatles.ru
Tick level data insight on Arcellx Inc. volatilityWeekly Gains Report & Capital Efficient Trade Techniques - Newser
Has Arcellx Inc. formed a bullish divergenceJuly 2025 Trends & Safe Capital Growth Tips - Newser
Long term hold vs stop loss in Arcellx Inc.2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How Arcellx Inc. stock performs during market volatilityEarnings Overview Report & Expert Approved Momentum Ideas - Newser
Pattern recognition hints at Arcellx Inc. upsideWeekly Investment Report & Verified Momentum Watchlists - Newser
Combining price and volume data for Arcellx Inc.Market Growth Review & Pattern Based Trade Signal System - Newser
Do Higher Losses at Arcellx (ACLX) Reflect a Strategic Shift or Growing Pains? - simplywall.st
Financial Analysis: Arcellx (NASDAQ:ACLX) and Astria Therapeutics (NASDAQ:ATXS) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Backtesting results for Arcellx Inc. trading strategies2025 Buyback Activity & Expert Curated Trade Setup Alerts - Newser
Real time scanner hits for Arcellx Inc. explainedQuarterly Risk Review & Daily Price Action Insights - Newser
Will Arcellx Inc. stock go up soon2025 Fundamental Recap & Technical Buy Zone Confirmations - Newser
Is Arcellx Inc. stock a buy or sellPortfolio Profit Report & Stepwise Trade Signal Guides - thegnnews.com
Heatmap analysis for Arcellx Inc. and competitorsMarket Activity Recap & Free Weekly Chart Analysis and Trade Guides - Newser
Is Arcellx Inc. a candidate for recovery play2025 Risk Factors & Weekly Watchlist for Consistent Profits - Newser
Historical volatility pattern of Arcellx Inc. visualized2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser
Is Now a Good Time to Reenter Arcellx Inc.Risk Management & Low Risk Investment Opportunities - 선데이타임즈
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs - MSN
Widening Losses in Q2 and H1 Might Change the Case for Investing in Arcellx (ACLX) - simplywall.st
Applying big data sentiment scoring on Arcellx Inc.Free Daily Picks With Predictable Performance - Newser
Smart tools for monitoring Arcellx Inc.’s price actionFree Chart Driven High Reward Trading Setup - Newser
Is this a good reentry point in Arcellx Inc.Future Growth Stock Forecasting Strategy - Newser
Evercore Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Evercore ISI Maintains Buy Rating on Arcellx Inc with $115 Price Target - AInvest
Why Arcellx Inc. stock attracts strong analyst attentionDaily Upside Movement Prediction With Data - Newser
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Can you recover from losses in Arcellx Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results - simplywall.st
We Think Arcellx (NASDAQ:ACLX) Can Afford To Drive Business Growth - Yahoo Finance
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $134 - 富途牛牛
Canaccord Genuity Sticks to Its Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Using Ichimoku Cloud for Arcellx Inc. technicalsOversold Opportunity Scanner with RSI Data - Newser
Using Bollinger Bands to evaluate Arcellx Inc.Near-Term Market Opportunity Forecast Sheet - Newser
Published on: 2025-08-08 23:14:52 - Newser
Arcellx Inc. stock volume spike explainedLoss Limitation Strategy Based on Analysis - Newser
Did Widening Losses and Falling Sales Just Shift Arcellx's (ACLX) Investment Narrative? - simplywall.st
Arcellx 2025 Q2 Earnings Deepened Losses Amid Declining Revenue - AInvest
Does Arcellx Inc. have a sustainable dividendShort-Term Explosive Growth - thegnnews.com
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating - TipRanks
Arcellx shares rise 3.32% intraday after reporting positive Q2 2025 financial results and potential life-changing therapy for multiple myeloma patients. - AInvest
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile - TipRanks
Arcellx earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating - TipRanks
Arcellx Inc Shares Dip Amid Revenue Concerns - TipRanks
Arcellx reports Q2 EPS (94c), consensus ($1.03) - TipRanks
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Arcellx Q2 Revenue Misses Estimates, Adjusted EPS Beats Consensus - AInvest
Earnings Flash (ACLX) Arcellx, Inc. Reports Q2 Revenue $7.6M, vs. FactSet Est of $13.5M - MarketScreener
Arcellx Inc (ACLX) 財務データ
収益
当期純利益
現金流量
EPS
Arcellx Inc (ACLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Patel Kavita | Director |
Jun 10 '25 |
Sale |
67.36 |
1,500 |
101,040 |
0 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):